Article Text

Download PDFPDF

250 Chimeric antigen receptors containing CD30-derived costimulatory domain elicit augmented T cell effector functions and anti-tumor efficacy
  1. Hyun-Il Cho,
  2. Chung-Hyo Kang,
  3. Sang-Eun Lee,
  4. In-Sil Song,
  5. Jung-Min Ha,
  6. Hyun-Jung Sohn and
  7. Tai-Gyu Kim
  1. VGeCell Inc., Seoul, Republic of Korea


Background Adoptive cell therapy utilizing chimeric antigen receptor (CAR)-engineered T cells has demonstrated a feasible, attractive “off-the-shelf” approach against numerous types of cancers. Successful tumor eradication depends primarily on providing optimized costimulatory signals capable of achieving robust CAR-T cell proliferation, persistence, and antitumor reactivity. Here, we assessed the capability of a novel CD30-derived costimulatory domain, a known TNFR superfamily member involved in anti-apoptosis as well as cell activation and proliferation, to generate effective CAR-T cells.

Methods We designed CD19-redirecting second-generation CARs incorporating the intracellular signaling domain of CD30 and evaluated the immune-phenotype, cytokine secretion, and real-time cytolytic activity of CAR-transduced T cells against CD19-expressing cells in comparison with other CARs containing CD28 or 4-1BB costimulatory domains. Subsequentially, their therapeutic efficacy was assessed with a pre-clinical Nalm-6-bearing xenogeneic model. We also engineered third-generation CARs combining CD30 and either CD28 or 4-1BB and conducted multiple repeat in vitro experiments evaluating their proliferation and cytolytic functionality against CD19-expressing tumors. Further, we tested the efficacy of third-generation CAR signaling after alteration with glypican-3 or mesothelin-targeting single chain fragment variable (scFv) domains.

Results T cells activated by a CD30-ζ signaling-CAR displayed enhanced effector functions with similar levels of proliferation, cytolytic efficacies, and cytokine secretion in vitro against CD19-expressing cancer cells as those of other CARs with CD28 or 4-1BB costimulatory domain, which are currently in clinical use. Administration of CD30-containing CAR-T cells into tumor-bearing mice resulted in improved human T cell persistence and tumor regression in a xenogeneic allograft model, which was similar to those achieved with CD28- or 4-1BB–signaling CAR-T cells. Furthermore, third-generation CARs including CD30 with either CD28 or 4-1BB costimulatory domain retained potent antitumor efficacies independent of their position. More significantly, CAR-T cells containing CD30-signaling revealed effective cytolytic activities against several solid cancer cell lines based on its scFv fragments.

Conclusions Our results demonstrate that the CD30-derived costimulatory domain could be an alternative for developing CAR-engineered therapeutics which may be applicable for various design of CAR constructs, with an emphasis on effectiveness against solid tumors.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.